Fate Therapeutics (FATE) Misses Q4 EPS by 5c

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.72), $0.05 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $10.73 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Fate Therapeutics to present FT819 systemic sclerosis data at ISSCR
• Intercontinental Exchange (ICE) PT Lowered to $208 at Raymond James, 'we view the risk/reward as attractive'